ScreenerHero

ALNY Alnylam Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · alnylam.com
219.89USD+0.08%Mkt Cap: 29.42B $P/E: 37.08

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for h…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD
TWST
Twist Bioscience Corporation
$13.59BUSD

Key Statistics

Company
Market Cap29.42B USD
Enterprise Value29.08B USD
Revenue (TTM)4.80B USD
Gross Profit3.03B USD
Net Income (TTM)313.75M USD
Revenue/Share36.24 USD
Last Price219.89 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)37.08
P/E (Forward)17.62
PEG0.28
EV/EBITDA27.58
EV/Revenue6.05
P/S6.12
P/B21.70
EPS (TTM)5.93
EPS (Forward)12.47
52W Range
197.817% of range495.55
52W High495.55 USD
52W Low197.81 USD
Profitability
Gross Margin81.64%
Oper. Margin17.93%
EBITDA Margin21.95%
Profit Margin8.45%
ROE39.76%
ROA6.32%
Growth
Revenue Growth66.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF524.08M USD
CapEx (TTM)58.70M USD
FCF Margin5.65%
FCF Yield0.92%
Net Debt-320.66M USD
Net Debt/EBITDA-0.30
Balance Sheet
Debt/Equity1.62
Current Ratio3.06
Quick Ratio2.79
Book Value/Sh10.13 USD
Cash/Share24.72 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)371.12 USD
Upside (mean)+68.8%
Target Range256.00 USD – 536.00 USD
256.00+68.8% to mean536.00
# Analysts26
Ownership
Shares Out.133.81M
Float133.24M
Insiders0.18%
Institutions101.82%
Short Interest
Short Ratio4.2d
Short % Float7.16%
Short % Out.5.38%
Shares Short7.19M
Short (prev mo.)4.77M
Technical
SMA 50241.49 (-8.9%)
SMA 200302.88 (-27.4%)
Beta0.30
S&P 52W Chg14.58%
Avg Vol (30d)1.52M
Avg Vol (10d)1.24M
Technical Indicators
RSI (14)34.6
MACD-4.5348
MACD Signal-1.3932
MACD Hist.-3.1416
BB Upper272.81 USD
BB Middle247.39 USD
BB Lower221.96 USD
BB Width20.55%
ATR (14)10.83 USD
Vol Ratio (20d)0.83x